Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Launched by NANJING MEDICAL UNIVERSITY · Aug 6, 2019
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into whether pancreatic cancer can cause a condition called heterotopic ossification, which is when bone forms in places where it shouldn't, such as in the abdominal area after surgery. Researchers want to understand how this happens, especially in patients who have had surgery for pancreatic cancer. The study is not yet recruiting participants, but when it begins, it will focus on people aged 65 to 74 years.
To be eligible for this trial, participants must provide consent and have had a specific type of abdominal surgery where the incision was closed in a particular way. However, individuals who have a history of other cancers, previous surgeries in the mid-abdomen, or certain metabolic conditions affecting calcium and phosphorus will not be able to join. Participants can expect to contribute to important research that may help improve understanding and treatment of complications related to pancreatic cancer surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Obtain informed consent from the patients.
- • The patient's abdominal incision was double-closed with continuous suture of linea alba and fascia with absorbable suture, and skin was sutured with skin staples.
- Exclusion Criteria:
- • Refusing to join the study
- • Previous history of malignant tumor
- • Previous history of midabdominal incision
- • Abnormal calcium and phosphorus metabolism
- • Distant metastasis
- • Palliative operation
- • performing neoadjuvant chemotherapy
About Nanjing Medical University
Nanjing Medical University is a leading institution in medical education and research, dedicated to advancing health care through innovative clinical trials and scientific inquiry. With a strong emphasis on translating research findings into practical applications, the university fosters collaboration among multidisciplinary teams to address pressing health issues. Committed to ethical standards and patient safety, Nanjing Medical University is at the forefront of clinical research, contributing valuable insights and advancements in medical science to improve patient outcomes and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Yi Miao, Prof.
Principal Investigator
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University
Junli Wu, MD,PHD
Study Director
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University
Jishu Wei, MD,PHD
Principal Investigator
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials